申请人:LEBRETON Luc
公开号:US20080119465A1
公开(公告)日:2008-05-22
Sulfonylindoline compounds of formula I,
wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.
公式I的磺胺基吲哚化合物,其中R1至R4,Y和Z具有定义的含义,一种制备这种化合物的过程,以及用作药用活性物质,特别用于治疗或抑制神经退行性疾病、心血管疾病、炎症性疾病、高胆固醇血症、血脂异常、肥胖或糖尿病。